Human Adenosine A2A Receptor Recombinant Cell Line, HEK293 (CAT#: IOC-LX074)

Creative Biolabs has developed several immune checkpoint stable cell Lines expressing the most popular immune checkpoints to accelerate clients' immunotherapy discovery and clinical translation. Adenosine A2a receptor (A2aR or ADORA2A) stably expressed in HEK-293 cells. Which can be used in binding assays and functional assay.

Stable cell lines for increased reliability and reproducibility;
Protein expression at the cell surface validated by FACS or WB;

• Screen for agonists or antagonists of A2aR.
• Study PD-1 and CTLA-4 combination therapy.
• Screen co-inhibitor immune checkpoint molecules for cancer immunotherapy.

Human

HEK293

Adenosine A2A Receptor

Adenosine signaling plays an important role in inflammation and the immune response. Many cells in the tumor microenvironment express ectopic CD39 and CD73, leading to the buildup of extracellular adenosine. Engagement of adenosine with the high affinity A2a receptor (A2aR) on the surface of T cells, macrophages, NK cells, neutrophils, and dendritic cells causes downregulation of the immune response. Therefore, A2aR is a novel immune checkpoint protein, and blockade of A2aR is being actively investigated as a potential immunotherapy. Several A2aR antagonists have progressed to clinical trials for the treatment of Parkinson's disease, and preclinical studies have confirmed that blockade of A2a receptor activation has the ability to markedly enhance anti-tumor immunity.